Allogene Therapeutics (ALLO) Earnings Yield: History & Chart

Allogene Therapeutics, Inc.(ALLO)

Biotechnology · South San Francisco, CA

$1.45-0.05 (-3.67%)

Delayed quote: Oct 6, 2026, 3:45 PM EDT

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

151 employees

www.allogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zachary Roberts

View full financials

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Allogene Therapeutics, Inc. (ALLO)	$498.75M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$503.81M	N/A	8.34%	8.34%	8.34%
Crescent Biopharma, Inc. (CBIO)vs ›	$503.86M	N/A	N/A	N/A	N/A
Tactile Systems Technology, Inc. (TCMD)vs ›	$498.77M	4.88%	3.42%	5.62%	4.98%
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$504.56M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$491.66M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$511.18M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$516.33M	N/A	516.44%	516.44%	516.44%
Evolus, Inc. (EOLS)vs ›	$486.34M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$484.31M	5.43%	9.76%	11.41%	9.78%

NAME

MARKET CAP

EARNINGS YIELD

TTM

Allogene Therapeutics, Inc. (ALLO)

$498.75M

N/A

908 Devices Inc. (MASS)vs ›

$503.81M

N/A

8.34%

Crescent Biopharma, Inc. (CBIO)vs ›